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Objective: Crimean-Congo hemorrhagic fever (CCHF) is an acute viral hemorrhagic fever with a
high mortality rate. Despite increasing knowledge about viral hemorrhagic fevers, the pathogen-
esis of CCHF and causes of death have not been well described. In this study, we aimed to evaluate
the cardiac functions of CCHF patients.
Methods: This prospective study was performed among confirmed CCHF cases in Turkey in 2007.
All the patients underwent a thorough cardiologic evaluation and transthoracic echocardiography
examination within 24 hours of hospitalization. In addition, the patients were classified into two
groups — ‘severe’ CCHF and ‘non-severe’ CCHF. Demographic characteristics, findings of echo-
cardiography, and outcomes were recorded for each patient.
Results: Among 52 consecutive patients with a tentative diagnosis of CCHF, 44 were confirmed as
having CCHF. Seventeen (38.6%) patients were classified as severe, whereas the remaining 27
(61.4%) patients were classified as non-severe. Five of 17 severe CCHF patients died. Severe cases
had a lower left ventricular ejection fraction ( p = 0.04), a higher systolic pulmonary artery
pressure ( p = 0.02), and more frequent pericardial effusion ( p < 0.001) compared to non-severe
cases. Fatal CCHF cases also had a lower left ventricular ejection fraction ( p = 0.03), a higher
systolic pulmonary artery pressure (p = 0.03), and more frequent pericardial effusion ( p = 0.01)
compared to survivors.
Conclusions: The results of this study indicate that severe and fatal CCHF cases have impaired
cardiac functions, which may be associated with fatality in CCHF infection. Direct invasion of the
heart muscles by the virus or endothelial damage of cardiac structures may have a role in this.
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Molecular testing methods would be useful in order to investigate direct invasion by the CCHF
virus. Clinicians should be aware of this complication.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Crimean-Congo hemorrhagic fever (CCHF) is an acute viral
hemorrhagic fever (VHF) with a case fatality rate of 10—30%.
It is caused by infection with the CCHF virus, which belongs to
the genus Nairovirus of the family Bunyaviridae. CCHF was
first described in the 1940s, whenmore than 200 human cases
occurred in the Crimean peninsula of the former Soviet
Union, and it is now endemic in many different regions of
Africa, Asia, and Eastern Europe. Human beings become
infected through tick bites, by crushing infected ticks, after
contact with a patient with CCHF during the acute phase of
infection, or by contact with blood or tissues from viremic
livestock. The most important clinical features are fever and
in the most severe cases, shock and hemorrhage. Despite
increasing knowledge about hemorrhagic fever viruses, the
pathogenesis of CCHF and causes of death have not been well
described.1,2 It has been reported that mononuclear phago-
cytes, hepatocytes, and endothelial cells aremajor targets of
CCHF virus infection.3 However, to our knowledge, the data
available on the cellular targets and distribution of CCHF
virus in human tissues remain limited.
Fatal illness in VHF is characterized by rapid development
of refractory shock, severe coagulopathy, and multifocal
necrosis of the liver and other viscera.4 Factors contributing
to a fatal outcome for CCHF are reported to include severe
gastrointestinal hemorrhage, cerebral hemorrhage, severe
anemia and dehydration, and shock associated with pro-
longed diarrhea, myocardial infarction, lung edema, and
pleural effusion.5—9 However, several viral agents are known
to cause myocarditis and cardiomyopathy including hemor-
rhagic fever viruses.10—15 Cardiac involvement may have a
contributing role in the pathogenesis of shock in CCHF and
may also influence the outcome. To our knowledge, the
literature presents no echocardiographic studies on cardiac
involvement in patients with CCHF. This study was therefore
undertaken to elucidate data on cardiac involvement in CCHF
patients.
Materials and methods
After obtaining approval from the Human Ethics Committee
of Cumhuriyet University School of Medicine, 52 consecutive
patients who were hospitalized with a tentative diagnosis of
CCHF between June 1 and June 30, 2007 were enrolled in our
study. Informed consent was also obtained from the patients.
As per the protocol, all patients underwent a thorough
cardiologic evaluation by a cardiologist after hospitalization.
Following this, within 24 hours of hospitalization, all patients
underwent a transthoracic echocardiography examination
using an appropriate probe (Sonosite Inc., Bothell, WA,
USA); this was carried out by an echocardiographer who
was blinded to the study. The same echocardiographer mea-
sured the ventricular (by modified Simpson method) and
valvular functions, wall motion scores, presence of pericar-
dial effusion, pulmonary pressures, diastolic functions bymeasuring early diastolic mitral velocity (E wave) and late
diastolic mitral velocity (A wave), and the E/A ratio (normal
E/A ratio: 1—2) according to the recommendations of recent
guidelines.16 Electrocardiography (ECG) recordings were
obtained from all the patients. All the echocardiographic
data were recorded and evaluated offline by an experienced
cardiologist.
CCHF infection was suspected if a patient had an epide-
miologic risk factor (history of tick exposure and/or resident
in or traveled to a CCHF endemic region) plus an acute febrile
illness resembling VHF (oral temperature>38 8C) and throm-
bocytopenia (platelet count <150  109 cells/l) and/or
hemorrhagic manifestations. These patients were hospita-
lized immediately, and serum samples were obtained from all
for diagnostic studies. A convalescent phase serum sample
was obtained from each patient after at least 7 days when
possible. Acute and convalescent phase serum samples were
sent to the Virology Laboratory of Refik Saydam Hygiene
Central Institute, Ankara, Turkey for serologic and virologic
analyses. The definitive diagnosis of CCHF infection was
based upon typical clinical and epidemiological findings
and detection of CCHF virus-specific IgM by ELISA or of
genomic segments of the CCHF virus by reverse transcrip-
tion-polymerase chain reaction (RT-PCR) either in the acute
and/or convalescent phase of the disease. In the study, all
confirmed CCHF patients were classified into two groups in
terms of disease severity (‘severe’ and ‘non-severe’),
according to the predictive factors for fatal outcome
reported by Swanepoel and co-workers.5
Patients with pathological Q waves in their initial ECG,
patients with a previous history of cardiac disease, including
significant left-sided valvular disease, and patients using
anticoagulant drugs were not included in the study. All the
patients received appropriate therapy including supportive
care with intravenous fluids and platelet suspension, and
blood and fresh frozen plasma transfusion, when indicated.
Statistical analysis
The demographic characteristics and echocardiography find-
ings were recorded for each patient. The parametric data
were expressed as mean  SD and categorical data as per-
centages. Independent parameters were compared by
Mann—Whitney U-test. Proportions for categorical variables
were compared using the Chi-square test, although Fisher’s
exact test was used when the data were sparse. A p value of
0.05 was considered significant, using two-sided compar-
isons. SPSS (version 10.0) was used to perform statistical
procedures.
Results
In this study, the diagnoses of 44 out of 52 consecutive
patients with a tentative diagnosis of CCHF were verified.
Twelve (27.3%) of 44 patients had CCHF virus-specific IgM
antibodies, 2/44 (4.5%) had a positive RT-PCR test for CCHF
Table 1 Comparison of the demographic characteristics and echocardiography findings of the severe and non-severe Crimean-






Age (years), mean  SD 41.9  22.7 47.7  21.7 0.41
Female gender, n (%) 7 (41.2) 16 (59.3) 0.39
Hospitalization days, mean  SD 9.3  2.9 6.5  2.5 0.01
Fatal outcome, n (%) 5 (29.4) 0 0.01
Echocardiography findings:
Percent ejection fraction, mean  SD 50  7 55  9 0.04
Systolic pulmonary artery pressure (mmHg), mean  SD 48  6 36  10 0.02
Pericardial effusion, n (%) 13 (76.5) 6 (22.2) <0.001
Tricuspid regurgitation, n (%) 9 (52.9) 8 (29.6) 0.22
Global wall motion abnormality, n (%) 2 (11.8) 1 (3.7) 0.55
Wall motion abnormality on anterior wall, n (%) 3 (17.6) 2 (7.4) 0.36
Abnormal diastolic function up on abnormal E/A ratio,a n (%) 14 (82.4) 15 (55.6) 0.10
a E/A, early diastolic mitral velocity (E wave)/late diastolic mitral velocity (A wave).
CCHF: does it involve the heart? 371virus, and 30/44 (68.2%) were positive in both tests during
the acute and/or convalescent phase of the disease. Accord-
ing to the severity score,5 as defined previously, 17 (38.6%)
patients were classified as severe, whereas the remaining 27
(61.4%) patients were classified as non-severe. Of the 44
consecutive patients with CCHF, five (11.4%) of them died
during the hospitalization period.
Table 1 shows the demographic characteristics and echo-
cardiography findings of the severe and non-severe CCHF
patients. Severe CCHF patients had a significantly lower
ejection fraction (EF) than non-severe CCHF patients (50%
vs. 55%; p = 0.04) based on the echocardiographic examina-
tion, and a significantly higher systolic pulmonary artery
pressure ( p = 0.02) than non-severe CCHF patients. There
was a significant association between severity and the pre-
sence of pericardial effusion ( p < 0.001). Severity was also
associated with survival; five of 17 (29.4%) patients with
severe CCHF died, whereas none of the patients with non-
severe CCHF died ( p = 0.01).Table 2 Comparison of the demographic characteristics and echo
hemorrhagic fever (CCHF) patients.
Variable
Age (years), mean  SD
Female gender, n (%)
Echocardiography findings:
Percent ejection fraction, mean  SD
Systolic pulmonary artery pressure (mmHg), mean  SD
Pericardial effusion, n (%)
Tricuspid regurgitation, n (%)
Global wall motion abnormality, n (%)
Wall motion abnormality on anterior wall, n (%)
Abnormal diastolic function up on abnormal E/A ratio,a n (%)
a E/A, early diastolic mitral velocity (E wave)/late diastolic mitral vTable 2 presents the demographic characteristics and
echocardiography findings of the fatal and non-fatal CCHF
patients. In the patients with fatal CCHF, the mean EF was
significantly lower, whereas the mean systolic pulmonary
artery pressure was significantly higher than in those with
non-fatal CCHF ( p = 0.03). Although all of the fatal CCHF
patients had varying degrees of pericardial effusion, 35.9% of
non-fatal CCHF patients had pericardial effusion ( p = 0.01).
When EF was subclassified into depressed EF (<50%) or
normal EF (50%), it was found that four out of five fatal
CCHF patients had depressed EF, while 25.6% of the non-fatal
CCHF patients had depressed EF ( p = 0.03).
Discussion
To date, the specific mechanisms underlying the pathogen-
esis of CCHF infection have not been clearly explained.1,2,17






50.4  23.6 44.8  22.1 0.62
3 (60) 20 (51.3) 1.00
45  9 54  8 0.03
50  6 39  9 0.03
5 (100) 14 (35.9) 0.01
4 (80) 13 (33.3) 0.07
2 (40) 1 (2.6) 0.03
3 (60) 2 (5.1) 0.01
5 (100) 24 (61.5) 0.15
elocity (A wave).
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tion, and shock.1,6—8 Mononuclear phagocytes, hepatocytes,
and endothelial cells are major targets for the CCHF virus
during the course of the infection.3 In particular, infection of
the endothelium has an important role in CCHF pathogenesis.
Endothelial damage contributes to hemostatic failure by
stimulating platelet aggregation and degranulation, with
consequent activation of the intrinsic coagulation cas-
cade.2—9 In VHFs, impairment of endothelial cell function
can cause a wide range of vascular effects that lead to
changes in vascular permeability or hemorrhage.17 Increased
vascular permeability leads to the hypovolemic shock in
dengue shock syndrome (DSS) by leakage of water, proteins,
and electrolytes from the vascular compartment.11 On the
other hand, it is probable that the endothelium plays a role in
the pathogenesis of VHF through the secretion of cytokines
and other inflammatory mediators.3 Recently, the serum
levels of tumor necrosis factor (TNF)-a and interleukin
(IL)-6 were found to be higher in fatal than non-fatal CCHF
cases.18
The most comprehensive study of the clinical pathology of
CCHF is that of Swanepoel et al.,5 in which observations were
made on 50 CCHF patients in South Africa diagnosed between
1981 and 1987. Of the 50 patients studied, 15 patients who
died had developed terminal multiple organ failure and
pulmonary insufficiency. Another histopathological study
showed hepatocellular necrosis in all and splenic lymphoid
depletion and necrosis in 11 of 12 fatal CCHF cases. In that
study, congestion and interstitial edema in the heart tissues
of one fatal CCHF case were also shown.3 The observation of
cardiac congestion and edema in that fatal CCHF case may
support cardiac involvement. However, little is known about
the effect of CCHF virus on the heart.
Although myocarditis and cardiomyopathy can be caused
by several different viruses, the Coxsackie A and B viruses and
adenovirus are the most frequent agents amongst them.10,14
Both immune and direct viral cytotoxic mechanisms of myo-
cardial tissue destruction are important in the pathogenesis
of viral myocarditis. Natural killer cells, T lymphocytes, and
various cytokines, including interleukin (IL)-1b, TNF-a, inter-
feron-g, and IL-10 may have both beneficial and deleterious
effects on myocardial function. The direct effects of virus-
mediated cytotoxicity include focal necrosis of myocytes
without inflammatory cell infiltrate.14 It has been shown
previously in experimental and clinical studies that hemor-
rhagic fever viruses are also able to cause cardiac involve-
ment. Histologic myocardial lesions, including focal
lymphoblastic infiltrates, vascular ruptures, and mild inter-
stitial reactive change demonstrating cardiac involvement
have been observed in experimental Junin virus-infected
monkeys.13 Dengue virus and yellow fever virus, members
of the Flavivirus genus of the Flaviviridae family, can also
cause cardiac involvement in humans.10,11,15,19 Hantavirus
belonging to the Bunyaviridae family, the same family as that
of the CCHF virus, causes hantavirus pulmonary syndrome
(HPS). Recently, it has been reported that the presence of
hantaviral antigen in the cardiac endothelium and interstitial
macrophages in the hearts of 14 individuals who died of HPS
strongly suggests typical myocarditis in HPS.12 Molecular
testing of heart muscle endothelium for the presence of
CCHF virus by RT-PCR, and culture of the heart tissues would
be useful in order to investigate direct invasion by CCHFvirus. However, myocardial biopsy could be fatal due to the
low platelet count in CCHF patients.
Echocardiography may be helpful but is not diagnostic in
viral myocardial involvement.10,14,20 Left ventricular systolic
dysfunction reflecting a myocarditic process is common in
patients with congestive heart failure. Additional findings are
right ventricular dysfunction, hypo-asynergic ventricular
areas, left ventricular hypertrophy, hyper-refractile myocar-
dial areas, ventricular thrombi, and restrictive ventricular
filling.20 In the present study, CCHF patients had a consider-
able amount of cardiac involvement.
In this study group, EF was significantly more depressed in
the severe CCHF group compared to the non-severe CCHF
group. It was also significantly more depressed in the fatal
CCHF patients than in the non-fatal CCHF patients. In addi-
tion to this, the severe and the fatal CCHF patients had more
frequent involvement of the pericardium and right ventricle
than the non-severe and non-fatal CCHF patients. The echo-
cardiography findings of 17 dengue hemorrhagic fever (DHF)/
DSS patients are comparable with our findings.11 In that
study, the mean EF was reported to be 47% in 17 DHF patients
and 39% in DSS patients. Depressed cardiac functions are an
important component of viral VHF even in the absence of
direct myocardial infection.21 The depressed cardiac func-
tions of our patients might have been due to involvement of
the myocardium by the CCHF virus12 and/or myocardial
endothelial injury.2,11,17,22 Further studies are needed to
determine the pathogenesis of myocardial involvement in
CCHF. We believe that depressed cardiac functions may cause
shock and fatal outcomes in the severe form of CCHF.
In conclusion, CCHF presents with considerable cardiac
involvement. We conclude that cardiac involvement during
the course of the disease may affect fatality and the severity
of CCHF, and thus, clinicians should be aware of this com-
plication. Our study presents preliminary findings to enable
and justify further studies, and describes for the first time in
the literature the association between CCHF and cardiac
abnormalities diagnosed by echocardiography, a frequently
used noninvasive diagnostic tool for the evaluation of heart.
We believe that further studies will show myocardial involve-
ment in CCHF in the light of our initial findings.
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